Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Broadcom secures role as key Apple supplier with chip deal through 2031
Novavax (NVAX) Cuts Full-Year Forecast as Vaccine Sales Decline
August 8, 2022 4:26 PM EDTAmerican biotechnology company Novavax (NASDAQ: NVAX) reported earnings aftermarket Monday.
The company reported a loss per share of $6.53, $12.03 worse than the analyst estimate of $5.50, and widening from the loss of $4.75 per share during the same period in 2021. Meanwhile, revenue fell year-over-year to $186... More
Novavax (NVAX) Misses Q2 EPS by $12.03, Cuts FY Guidance
August 8, 2022 4:07 PM EDTNovavax (NASDAQ: NVAX) reported Q2 EPS of ($6.53), $12.03 worse than the analyst estimate of $5.50. Revenue for the quarter came in at $186 billion versus the consensus estimate of $1.02 billion.
GUIDANCE:
Novavax sees FY2022 revenue of $2-2.3 billion, versus the consensus of $4.27... More
